SanBio Company Limited Stock OTC Markets
Equities
SNBOY
US7995731004
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.81 USD | -48.72% | -.--% | -.--% |
03-19 | SanBio Eyes Approval for Brain Injury Treatment Drug SB623 By March | MT |
03-19 | Jefferies Adjusts SanBio’s Price Target to 270 Yen From 310 Yen, Keeps at Underperform | MT |
Sales 2025 * | - | Sales 2026 * | 660M 4.24M 5.79M | Capitalization | 29.37B 189M 258M |
---|---|---|---|---|---|
Net income 2025 * | -3.3B -21.15M -28.91M | Net income 2026 * | -3.53B -22.64M -30.95M | EV / Sales 2025 * | - |
Net Debt 2025 * | 226M 1.45M 1.98M | Net Debt 2026 * | 3.03B 19.47M 26.62M | EV / Sales 2026 * | 49.1 x |
P/E ratio 2025 * |
-8.72
x | P/E ratio 2026 * |
-8.17
x | Employees | 29 |
Yield 2025 * |
-
| Yield 2026 * |
-
| Free-Float | 71.15% |
Latest transcript on SanBio Company Limited
1 day | -48.72% |
Managers | Title | Age | Since |
---|---|---|---|
Keita Mori
CEO | Chief Executive Officer | 56 | 13-02-26 |
Shinya Hirata
CTO | Chief Tech/Sci/R&D Officer | - | - |
Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Noboru Kotani
BRD | Director/Board Member | 67 | 13-02-28 |
Keita Mori
CEO | Chief Executive Officer | 56 | 13-02-26 |
Toru Kawanishi
CHM | Chairman | 56 | 13-02-26 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- 4592 Stock
- SNBOY Stock